CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Clinical trial NCT06449586 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06449586
Sponsor: Ruijin Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hematologic Malignancy

Start date: 2024-07-01
Primary completion: 2026-06-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.